- Presentation to highlight positive outcomes of Iomab-B led bone
marrow transplant in difficult to treat TP53 patients and the
mutation-agnostic mechanism of Actimab-A for patients with relapsed
or refractory acute myeloid leukemia
- Iomab-B and Actimab-A represent the only clinical stage
antibody radiation conjugates in development for patients with
acute myeloid leukemia
NEW
YORK, July 25, 2024 /PRNewswire/
-- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)
(Actinium or the Company), a leader in the development of Antibody
Radiation Conjugates (ARCs) and other targeted radiotherapies,
today announced that the Company will participate in the
3rd Annual Targeted Radiopharmaceuticals Summit US,
being held in San Diego, CA, from
July 30 – August 1, 2024. Actinium's presentation titled,
"Overcoming Adverse Cytogenetics, TP53, Other Mutations &
Treatment Resistant Disease in Relapsed/Refractory AML Using
Antibody Radiation Conjugates," will take place on Wednesday, July 31, 2024th. The
presentation will highlight the following:
- Exploring Iomab-B, a CD45 I-131 ARC, to enable bone marrow
transplant (BMT) in otherwise ineligible patients, while Actimab-A,
a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
- Outlining responses in heavily pretreated patients for both
Iomab-B and Actimab-A, including prior venetoclax treatment or
TP53-mutated disease, to demonstrate how targeted radiotherapies
offer broad therapeutic potential as backbone regimens
- Revealing preclinical data to further show the benefits of
combining Actimab-A with targeted therapies, such as FLT3
inhibitors, to enhance anti-tumor response
For more information about the Targeted Radiopharmaceutical
Summit and the conference agenda, please visit
https://targeted-radiopharma-us.com/.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA
(EU)), an induction and conditioning agent prior to bone marrow
transplant, and Actimab-A (Cooperative Research and Development
Agreement (CRADA) with the National Cancer Institute), a
therapeutic agent, have demonstrated potential to extend survival
outcomes for people with relapsed and refractory acute myeloid
leukemia. Actinium plans to advance Iomab-B for other blood cancers
and next generation conditioning candidate Iomab-ACT to improve
cell and gene therapy outcomes. Actinium holds more than 230
patents and patent applications including several patents related
to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please
visit: https://www.actiniumpharma.com/
Contact:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-at-the-3rd-annual-targeted-radiopharmaceuticals-summit-us-302206068.html
SOURCE Actinium Pharmaceuticals, Inc.